Epigenetic drivers of tumourigenesis and cancer metastasis

Seminars in Cancer Biology, Journal Year: 2017, Volume and Issue: 51, P. 149 - 159

Published: Aug. 14, 2017

Since the completion of first human genome sequence and advent next generation sequencing technologies, remarkable progress has been made in understanding genetic basis cancer. These studies have mainly defined changes as either causal, providing a selective advantage to cancer cell (a driver mutation) or consequential with no (not directly passenger mutation). A vast unresolved question is how primary becomes metastatic what are molecular events that underpin this process. However, extensive efforts indicate mutation may not be causal factor for transition. On other hand, epigenetic dynamic nature therefore potentially play an important role determining phenotypes area research just starting appreciated. Unlike studies, current limitations studying metastasis include lack conceptual analytical framework identifying putative changes. In review, we discuss key concepts involved alterations cascade. We particularly focus on events, describe approaches biological frameworks distinguishing between "epi-driver" "epi-passenger" metastasis. Finally, suggest potential directions future research.

Language: Английский

---

Toward the Early Detection of Cancer by Decoding the Epigenetic and Environmental Fingerprints of Cell-Free DNA

Cancer Cell, Journal Year: 2019, Volume and Issue: 36(4), P. 350 - 368

Published: Oct. 1, 2019

Language: Английский

---

Tumor-Educated Platelets as a Noninvasive Biomarker Source for Cancer Detection and Progression Monitoring

Cancer Research, Journal Year: 2018, Volume and Issue: 78(13), P. 3407 - 3412

Published: June 19, 2018

Liquid biopsies represent a potential revolution in cancer diagnostics as noninvasive method for detecting and monitoring diseases, complementary to or even replacing current tissue biopsy approaches. Several blood-based biosources biomolecules, such cell-free DNA RNA, proteins, circulating tumor cells, extracellular vesicles, have been explored molecular test development. We recently discovered the of tumor-educated blood platelets (TEP) biomarker trove RNA panels. TEPs are involved progression spread several solid tumors, spliced TEP surrogate signatures can provide specific information on presence, location, characteristics cancers. So far, samples from patients with different types, including lung, brain, breast cancers, tested, it has shown that distinct those inflammatory other noncancerous diseases. It remains be investigated how "educated," which mechanisms cause intraplatelet splicing, whether relative contribution platelet subpopulations changes cancer. Ultimately, may complement currently used biomolecules employed liquid diagnosis, potentially enhancing detection an early stage facilitating disease monitoring. Cancer Res; 78(13); 3407-12. ©2018 AACR.

Language: Английский

---

Clinical applications of the CellSearch platform in cancer patients

Advanced Drug Delivery Reviews, Journal Year: 2018, Volume and Issue: 125, P. 102 - 121

Published: Feb. 1, 2018

Language: Английский

---

Profiling circulating tumour cells and other biomarkers of invasive cancers

Nature Biomedical Engineering, Journal Year: 2018, Volume and Issue: 2(2), P. 72 - 84

Published: Feb. 3, 2018

Language: Английский

---

Utility of circulating tumor DNA in cancer diagnostics with emphasis on early detection

BMC Medicine, Journal Year: 2018, Volume and Issue: 16(1)

Published: Sept. 4, 2018

Various recent studies have focused on analyzing tumor genetic material released into the blood stream, known as circulating DNA (ctDNA). Herein, we describe current research application of ctDNA to cancer management, including prognosis determination, monitoring for treatment efficacy/relapse, selection, and quantification size disease burden. Specifically, examine utility early diagnostics focusing development a test detect in asymptomatic individuals by sequencing mutations ctDNA. Next, discuss prospect using cancer, present our calculations based previously published empirical findings prenatal diagnostics. We show that very stage (asymptomatic) tumors are not likely release enough be detectable typical draw 10 mL. Data also presented showing free can found healthy will difficult distinguish from those associated with cancer. conclude test, addition its high cost complexity, suffer same issues low sensitivity specificity traditional biomarkers when applied population screening diagnosis.

Language: Английский

---

Cell-Free DNA and Apoptosis: How Dead Cells Inform About the Living

Trends in Molecular Medicine, Journal Year: 2020, Volume and Issue: 26(5), P. 519 - 528

Published: Feb. 17, 2020

Language: Английский

---

Longitudinal Liquid Biopsy and Mathematical Modeling of Clonal Evolution Forecast Time to Treatment Failure in the PROSPECT-C Phase II Colorectal Cancer Clinical Trial

Cancer Discovery, Journal Year: 2018, Volume and Issue: 8(10), P. 1270 - 1285

Published: Aug. 30, 2018

Sequential profiling of plasma cell-free DNA (cfDNA) holds immense promise for early detection patient progression. However, how to exploit the predictive power cfDNA as a liquid biopsy in clinic remains unclear. RAS pathway aberrations can be tracked monitor resistance anti-EGFR monoclonal antibodies patients with metastatic colorectal cancer. In this prospective phase II clinical trial single-agent cetuximab

Language: Английский

---

Circulating biomarkers in patients with glioblastoma

British Journal of Cancer, Journal Year: 2019, Volume and Issue: 122(3), P. 295 - 305

Published: Oct. 31, 2019

Abstract Gliomas are the most common tumours of central nervous system and aggressive form is glioblastoma (GBM). Despite advances in treatment, patient survival remains low. GBM diagnosis typically relies on imaging techniques postoperative pathological diagnosis; however, both procedures have their inherent limitations. Imaging modalities cannot differentiate tumour progression from treatment-related changes that mimic progression, known as pseudoprogression, which might lead to misinterpretation therapy response delay clinical interventions. In addition limitations, tissue biopsies invasive time be performed over course treatment evaluate ‘real-time’ dynamics. an attempt address these liquid been proposed field. Blood sampling a minimally procedure for endure could provide tumoural information guide therapy. Tumours shed content, such circulating cells, cell-free nucleic acids, proteins extracellular vesicles, into circulation, biomarkers reported cross blood–brain barrier. The use emerging field GBM. this review, we aim summarise current literature biomarkers, namely DNA vesicles potential non-invasively sampled manage patients with

Language: Английский

---

Liquid Biopsy: Current Status and Future Perspectives

Oncology Research and Treatment, Journal Year: 2017, Volume and Issue: 40(7-8), P. 404 - 408

Published: Jan. 1, 2017

Cancer patients usually receive therapies according to their primary tumor's molecular traits. These characteristics may change during the evolution of distant metastases as leading cause cancer deaths. Primary tumor tissue, if accessible at all, does not always provide enough information stratify individual most promising therapy. Re-analysis metastatic lesions by needle biopsy is possible but invasive, and limited known intra-patient heterogeneity lesions. hurdles might be overcome analyzing cells or cell products in blood samples (liquid biopsy), which principle reflect all subclones present that specific time point allow sequential monitoring disease evolution. Liquid biopsies inform on circulating well tumor-derived cell-free nucleic acids, exosomes platelets. Here, we introduce different approaches blood-based liquid discuss clinical applications oncology.

Language: Английский

---